A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study)

Publications

>

Article

A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study)

Publicated to:EuroIntervention. 12 (13): 1587-1594 - 2017-01-01 12(13), DOI: 10.4244/EIJ-D-16-00128

Authors: García-Touchard A; Goicolea J; Sabaté M; Alfonso F; Ruiz-Salmerón R; Bethencourt A; Gonzalo N; Miranda F; Del Blanco B; Jiménez-Mazuecos J; Melgares R; Martínez-Romero P; Hernandez-García J; Lezaún R; Bullones J; Fernández-Portales J; Rumoroso J; Ortas R; Valdés M; Trillo R; Brugaletta S; Otzuki S; Hernández-Pérez F; Alonso-Pulpón L

Affiliations

Complejo Hosp Univ Albacete, Albacete, Spain - Author

Hosp Arnau Vilanova, Lleida, Spain University Hospital Arnau de Vilanova - Author

Hosp Carlos Haya, Malaga, Spain Hospital Carlos Haya - Author

Hosp Clin Barcelona, Barcelona, Spain Hospital Clinic de Barcelona University of Barcelona - Author

Hosp Clin San Carlos, Madrid, Spain Hospital Clinico San Carlos - Author

Hosp Clin Univ Santiago, La Corttna, Spain - Author

Hosp del Mar, Barcelona, Spain Institut Hospital del Mar d'Investigacions Mediques (IMIM) Hospital del Mar - Author

Hosp Galdakao Usansolo, Galdakao, Spain Galdakao Hospital - Author

Hosp Princesa, Madrid, Spain Hospital de La Princesa - Author

Hosp Puerto Real, Puerto Real, Spain Universidad de Cadiz Hospital Universitario Puerto Real - Author

Hosp San Pedro de Alcantara, Caceres, Spain - Author

Hosp Univ Navarra, Navarra, Spain University of Navarra - Author

Hosp Univ Puerta de Hierro Majadahonda, Dept Intervent Cardiol, Manuel Falla,1, Majadahonda 28220, Spain. Hospital Puerta de Hierro-Majadahonda - Author

Hosp Univ Puerta Hierro, Majadahonda, Spain Hospital Puerta de Hierro-Majadahonda - Author

Hosp Univ Son Espases, Balearic Islands, Spain Hospital Universitario Son Espases - Author

Hosp Univ Vall Hebron, Barcelona, Spain Hospital Universitari Vall d'Hebron - Author

Hosp Univ Virgen De La Victoria, Malaga, Spain Universidad de Malaga Hospital Virgen de la Victoria - Author

Hosp Univ Virgen de las Nieves, Granada, Spain Hospital Universitario Virgen de las Nieves - Author

Hosp Virgen Arrixaca, Murcia, Spain Hospital Clinico Universitario Virgen de la Arrixaca - Author

Hosp Virgen Macarena, Seville, Spain Hospital Universitario Virgen Macarena - Author

Abstract

Our aim was to assess the safety and efficacy of paclitaxel-eluting balloon (PTX-B) treatment after bare metal stent (BMS) implantation in patients undergoing primary angioplasty.After BMS implantation, patients were randomised (1:1) to treatment with a PTX-B or no PTX-B treatment (BMS group). The primary endpoint was in-stent late luminal loss (LLL) at nine-month follow-up. OCT was carried out on the first 20% of consecutive patients included in the study. Two hundred and twenty-three patients were randomised (BMS: 112, PTX-B: 111). At nine months, median LLL was 0.80 mm (interquartile range [IQR] 0.36-1.26) in the BMS group vs. 0.31 mm (IQR 0.00-0.58) in the PTX-B group, p<0.0001. Binary restenosis was significantly lower in the PTX-B group: 29.8% vs. 2.2%, p<0.0001, 95% confidence interval (CI): 3.2-54.2. Nine-month OCT showed good strut coverage in both groups but greater in the BMS group (100±0.0% vs. 99.52±1.11%, p=0.03) with very low rates of malapposed struts per lesion. One-year MACE was significantly lower in the PTX-B group (12.5% vs. 3.6%, p=0.016).PTX-B after successful BMS implantation resulted in less LLL and better clinical outcomes as compared with a BMS-only strategy. This was associated with good stent strut coverage and very low rates of malapposed struts.

Keywords

Myocardial infarctionPaclitaxel-eluting balloonPrimary angioplastySt-segment elevationStent

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal EuroIntervention due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2017, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 3.26, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

Field Citation Ratio (FCR) from Dimensions: 3.88 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-24, the following number of citations:

WoS: 14
Scopus: 14
Europe PMC: 5
OpenCitations: 13

Impact and social visibility

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Granada.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (ALONSO-PULPON RIVERA, LUIS ANTONIO).

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share